A/DT
review/NN
of/IN
drug/NN
knowledge/NN
discovery/NN
using/VBG
BioNLP/NN
and/CC
tensor/NN
or/CC
matrix/NN
decomposition/NN
./.
====================
Prediction/NN
of/IN
the/DT
relations/NNS
among/IN
drug/NN
and/CC
other/JJ
molecular/JJ
or/CC
social/JJ
entities/VBZ
is/VBZ
the/DT
main/JJ
knowledge/NN
discovery/NN
pattern/NN
for/IN
the/DT
purpose/NN
of/IN
drug-related/JJ
knowledge/NN
discovery/NN
./.
====================
Computational/JJ
approaches/NNS
have/VBP
combined/VBN
the/DT
information/NN
from/IN
different/JJ
resources/NNS
and/CC
levels/NNS
for/IN
drug-related/JJ
knowledge/NN
discovery/RB
,/,
which/WDT
provides/VBZ
a/DT
sophisticated/JJ
comprehension/NN
of/IN
the/DT
relationship/NN
among/IN
drugs/NNS
,/,
targets/NNS
,/,
diseases/NNS
,/,
and/CC
targeted/VBN
genes/NNS
,/,
at/IN
the/DT
molecular/JJ
level/NN
,/,
or/CC
relationships/NNS
among/IN
drugs/NNS
,/,
usage/NN
,/,
side/JJ
effect/NN
,/,
safety/RB
,/,
and/CC
user/NN
preference/NN
,/,
at/IN
a/DT
social/JJ
level/NN
./.
====================
In/IN
this/DT
research/NN
,/,
previous/JJ
work/NN
from/IN
the/DT
BioNLP/NN
community/NN
and/CC
matrix/NN
or/CC
tensor/JJ
decomposition/NN
was/VBD
reviewed/VBN
,/,
compared/VBN
,/,
and/CC
concluded/VBD
,/,
and/CC
eventually/RB
,/,
the/DT
BioNLP/NN
open-shared/JJ
task/NN
was/VBD
introduced/VBN
as/IN
a/DT
promising/JJ
case/NN
study/NN
representing/VBG
this/DT
area/NN
./.
====================
Drug-related/JJ
knowledge/NN
discovery/NN
is/VBZ
the/DT
process/NN
of/IN
discovering/VBG
novel/JJ
drug/NN
targets/NNS
,/,
drug-side/NN
effects/NNS
,/,
drug-drug/NN
interactions/NNS
(/(
DDIs/NNS
)/)
,/,
drug-disease/NN
or/CC
drug-indications/NNS
interactions/NNS
./.
====================
The/DT
novel/JJ
knowledge/NN
discovery/RB
has/VBZ
mainly/RB
led/VBD
to/TO
better/RBR
understanding/NN
of/IN
the/DT
molecular/JJ
bases/NNS
of/IN
drug/NN
efficacy/NN
,/,
and/CC
with/IN
focus/FW
on/IN
the/DT
application/NN
scenario/NN
of/IN
new/JJ
drug/NN
discovery/NN
,/,
drug/NN
development/NN
or/CC
drug/NN
repurposing/VBG
[/(
1/CD
]/)
,/,
i.e./FW
,/,
search/VBP
and/CC
replacement/JJ
of/IN
compounds/NNS
developed/VBD
for/IN
specific/JJ
diseases/NNS
[/(
2/CD
]/)
./.
====================
Drug/NN
discovery/NN
is/VBZ
usually/RB
initiated/VBN
by/IN
an/DT
experimental/JJ
method/NN
or/CC
computational/JJ
method/NN
./.
====================
Experimental/JJ
methods/NNS
,/,
either/CC
in/IN
vivo/FW
or/CC
in/IN
vitro/FW
,/,
are/VBP
more/RBR
acceptable/JJ
by/IN
the/DT
clinical/JJ
community/NN
./.
====================
However/RB
,/,
the/DT
disadvantages/NNS
of/IN
these/DT
methods/NNS
,/,
such/JJ
as/IN
cost/JJ
and/CC
time-consumption/NN
,/,
are/VBP
also/RB
obvious/JJ
./.
====================
The/DT
computational/JJ
way/NN
,/,
also/RB
known/VBN
as/IN
in/IN
silico/NN
method/NN
,/,
is/VBZ
mainly/RB
to/TO
perform/VB
the/DT
knowledge/NN
discovery/NN
under/IN
data/NNS
mining/VBG
instead/RB
of/IN
experimental/JJ
(/(
“/CD
wet/NN
lab/NN
”/CD
)/)
manipulations/NNS
./.
====================
Early/JJ
in/IN
2009/CD
,/,
a/DT
review/NN
in/IN
Nature/NN
[/(
3/CD
]/)
claimed/VBN
that/DT
in/IN
silico/NN
predictions/NNS
for/IN
drug/NN
discovery/NN
has/VBZ
come/VBN
of/IN
age/NN
,/,
and/CC
so/RB
far/RB
,/,
PubMed/JJ
has/VBZ
collected/VBN
over/IN
41/CD
thousand/CC
papers/NNS
about/RB
in/IN
silico/NN
drug/NN
knowledge/NN
discovery/RB
./.
====================
Generally/RB
,/,
in/IN
silico/JJ
methods/NNS
are/VBP
a/DT
computational/JJ
way/NN
to/TO
perform/VB
knowledge/NN
inference/IN
by/IN
using/VBG
data/NNS
mining/VBG
,/,
with/IN
less/RBR
time-consumption/JJ
and/CC
including/VBG
machine/NN
learning/VBG
,/,
molecular/JJ
docking/NN
,/,
pharmacophore/RB
structure/NN
,/,
structure-activity/NN
relationships/NNS
(/(
SAR/NN
)/)
,/,
quantitative/JJ
structure-activity/NN
relationship/NN
(/(
QSAR/NN
)/)
,/,
and/CC
combination/NN
methods/NNS
./.
====================
Drug-knowledge/NN
discovery/NN
with/IN
in/IN
silico/NN
methods/NNS
mainly/RB
identified/VBN
core/NN
molecular/JJ
entities/VBZ
,/,
including/VBG
genes/NNS
,/,
proteins/NNS
,/,
therapeutic/JJ
compounds/NNS
,/,
and/CC
other/JJ
“/JJ
omics/NNS
”/CD
information/NN
and/CC
henceforth/RB
,/,
to/TO
explore/VB
the/DT
novel/JJ
link/NN
between/IN
them/PRP
[/(
4/CD
]/)
./.
====================
Though/IN
chemoinformatics/NNS
methods/NNS
,/,
such/JJ
as/IN
SAR/NN
or/CC
QSAR/NN
,/,
have/VBP
made/VBN
great/JJ
success/NN
in/IN
screening/VBG
chemical/JJ
libraries/NNS
,/,
the/DT
huge/JJ
body/NN
of/IN
candidate/NN
chemical/JJ
compounds/NNS
has/VBZ
led/VBD
to/TO
overload/JJ
calculation/NN
and/CC
made/VBD
these/DT
methods/NNS
far/RB
from/IN
perfect/JJ
[/(
5/CD
]/)
./.
====================
Thanks/DT
to/TO
the/DT
rapid/JJ
emergence/NN
of/IN
deep/JJ
neural/JJ
network/NN
since/IN
the/DT
early/JJ
2010s/NNS
,/,
deep/RB
learning/VBG
strategies/NNS
have/VBP
undoubtedly/RB
manifested/VBN
their/PRP$
computational/JJ
advantage/NN
over/IN
chemoinformatics/NNS
strategies/NNS
for/IN
drug/NN
screening/NN
[/(
6/CD
]/)
,/,
and/CC
made/VBD
it/PRP
another/DT
application/NN
field/NN
of/IN
deep/JJ
neural/JJ
networks/NNS
./.
====================
In/IN
the/DT
meantime/NN
,/,
chemoinformatics/NNS
strategies/NNS
mainly/RB
focused/VBN
on/IN
novel/JJ
drug-target/NN
identification/NN
or/CC
DDIs/NNS
prediction/NN
,/,
instead/RB
of/IN
drug-side/JJ
effects/NNS
or/CC
drug-disease/NN
pairs/NNS
./.
====================
With/IN
higher/JJR
odds/NNS
of/IN
success/JJ
,/,
knowledge/NN
discovery/RB
tasks/VBZ
of/IN
recent/JJ
ones/NNS
relied/VBN
heavily/RB
on/IN
structured/JJ
knowledge/NN
entires/VBZ
came/VBD
from/IN
bioinformatics-based/JJ
data/NNS
base/NN
searching/VBG
or/CC
natural/JJ
language/NN
processing/NN
(/(
NLP/NN
)/)
–aided/VBD
automatical/JJ
curation.In/JJ
this/DT
review/NN
,/,
we/PRP
mainly/RB
focus/FW
on/IN
two/CD
typical/JJ
in/IN
silico/JJ
methods/NNS
of/IN
drug-related/JJ
knowledge/NN
discovery/RB
./.
====================
One/CD
method/NN
is/VBZ
text/JJ
mining/JJ
,/,
i.e./FW
,/,
Biomedical/JJ
Natural/JJ
Language/NN
Processing/JJ
(/(
BioNLP/NN
)/)
./.
====================
Another/DT
one/CD
is/VBZ
a/DT
knowledge/NN
discovery/NN
method/NN
,/,
with/IN
low/JJ
rank/NN
approximation/NN
of/IN
drug/NN
data/NNS
with/IN
a/DT
form/NN
of/IN
tensors/NNS
or/CC
matrices/NNS
./.
====================
As/IN
structured/JJ
knowledge/NN
entries/VBZ
were/VBD
supportive/JJ
to/TO
resolve/VB
most/JJS
drug-related/JJ
knowledge/NN
discovery/NN
tasks/NNS
,/,
NLP/NN
methods/NNS
are/VBP
regarded/VBN
as/IN
a/DT
good/JJ
addition/NN
to/TO
traditional/JJ
in/IN
silico/NN
methods/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
popularization/NN
of/IN
knowledge/NN
graphs/NNS
,/,
in/IN
recent/JJ
years/NNS
,/,
has/VBZ
dramatically/RB
encouraged/VBD
the/DT
promising/JJ
application/NN
of/IN
knowledge/NN
inference/VBP
in/IN
drug-related/JJ
knowledge/NN
discovery/NN
./.
====================
Tensors/NNS
or/CC
matrices/NNS
were/VBD
treated/VBN
as/IN
natural/JJ
data/NNS
structures/NNS
,/,
to/TO
contain/VB
drug/NN
knowledge/NN
entries/VBZ
,/,
and/CC
tensor/NN
or/CC
matrix/NN
decomposition/NN
served/VBD
as/IN
a/DT
rough/JJ
approximation/NN
of/IN
novel/JJ
link/NN
discovery/NN
./.
====================
Text/RB
resources/VBZ
and/CC
BioNLP/NN
methods/NNS
for/IN
drug-related/JJ
knowledge/NN
discovery/NN
====================
BioNLP/NN
is/VBZ
the/DT
application/NN
of/IN
NLP/NN
methods/NNS
to/TO
biomedical/JJ
entities/VBZ
such/JJ
as/IN
macromolecules/NNS
and/CC
relation/NN
extraction/NN
between/IN
protein-protein/JJ
or/CC
drug-drug/NN
interactions/NNS
./.
====================
As/IN
a/DT
hyponym/JJ
word/NN
for/IN
NLP/NN
,/,
the/DT
definition/NN
of/IN
BioNLP/NN
appeared/VBD
in/IN
the/DT
early/JJ
1990s/CD
[/(
7/CD
]/)
,/,
when/WRB
distributed/VBN
word/NN
representations/NNS
and/CC
applications/NNS
in/IN
BioNLP/NN
were/VBD
introduced/VBN
./.
====================
With/IN
the/DT
fast/JJ
accumulation/NN
of/IN
written/JJ
material/JJ
of/IN
scholarly/RB
publications/NNS
and/CC
clinical/JJ
narratives/NNS
,/,
the/DT
BioNLP/NN
community/NN
,/,
formed/VBD
in/IN
the/DT
late/JJ
1990s/CD
and/CC
various/JJ
named/VBN
entity/NN
recognition/NN
(/(
NER/NN
)/)
tools/NNS
were/VBD
developed/VBN
for/IN
the/DT
purpose/NN
of/IN
biomedical/JJ
applications/NNS
such/JJ
as/IN
DDIs/NNS
,/,
data/NNS
base/NN
curation/NN
,/,
ontology/RB
design/NN
,/,
and/CC
so/RB
on/IN
[/(
1/CD
]/)
./.
====================
In/IN
this/DT
section/NN
,/,
we/PRP
review/VBP
the/DT
development/NN
of/IN
BioNLP/NN
in/IN
drug-related/JJ
knowledge/NN
discovery/NN
by/IN
categorizing/VBG
the/DT
resources/NNS
for/IN
which/WDT
type/NN
of/IN
research/NN
was/VBD
performed/VBN
./.
====================
Three/CD
kinds/NNS
of/IN
text/JJ
resources/VBZ
,/,
i.e./FW
,/,
large-scale/JJ
curation/NN
data/NNS
,/,
small-scale/JJ
corpora/NN
,/,
and/CC
heterogeneous/JJ
data/NNS
,/,
were/VBD
introduced/VBN
,/,
as/IN
well/RB
as/IN
drug-related/VBN
discovery/NN
research/NN
approaches/NNS
based/VBN
on/IN
them/PRP
./.
====================
Here/RB
,/,
PubMed/JJ
and/CC
OMIM/NN
were/VBD
introduced/VBN
as/IN
two/CD
representatives/VBZ
of/IN
large-scale/JJ
curated/JJ
data/NNS
,/,
which/WDT
as/IN
a/DT
tradition/JJ
served/VBD
for/IN
drug-related/JJ
knowledge/NN
discovery/RB
for/IN
years/NNS
;/:
corpora/NN
emerged/VBN
from/IN
small-scale/JJ
data/NNS
aiming/VBG
for/IN
serving/VBG
high/JJ
quality/NN
text/RB
mining/JJ
upon/IN
large/JJ
text/RB
data/NNS
;/:
and/CC
finally/RB
,/,
multi-omics/NNS
data/NNS
was/VBD
introduced/VBN
as/IN
heterogeneous/JJ
data/NNS
./.
====================
Large/JJ
scale/NN
curation/NN
data/NNS
and/CC
drug-knowledge/NN
discovery/NN
in/IN
a/DT
wide/JJ
range/NN
====================
Released/VBN
for/IN
the/DT
first/JJ
time/NN
in/IN
1996/CD
,/,
PubMed/JJ
has/VBZ
long/JJ
been/VBN
the/DT
main/JJ
text/JJ
resources/VBZ
for/IN
the/DT
BioNLP/NN
community/NN
to/TO
collect/VB
references/VBZ
and/CC
abstracts/NNS
on/IN
life/NN
sciences/NNS
and/CC
biomedical/JJ
topics/NNS
[/(
8/CD
]/)
./.
====================
The/DT
2014/CD
version/NN
of/IN
PubMed/JJ
Medline/NN
was/VBD
explored/VBN
by/IN
Yang/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
through/IN
lexicon/NN
filtering/VBG
and/CC
dependency/NN
parsing/VBG
tree/CD
establishment/NN
./.
====================
They/PRP
used/VBN
trigger/VBP
word/NN
learning/VBG
to/TO
extract/NN
relationships/NNS
between/IN
diseases-genes/NNS
and/CC
genes-drugs/NNS
,/,
After/IN
obtaining/VBG
114,381/CD
disease-gene/JJ
and/CC
176,219/CD
gene-drug/NN
link/NN
pairs/NNS
,/,
an/DT
ABC/NN
model/NN
was/VBD
applied/VBN
to/TO
extract/NN
the/DT
indirect/JJ
link/NN
between/IN
disease/NN
and/CC
gene/NN
by/IN
considering/VBG
disease-gene/JJ
as/IN
A-B/NN
and/CC
gene-drug/NN
as/IN
B-C/NN
./.
====================
NER/NN
tools/NNS
were/VBD
developed/VBN
,/,
as/IN
well/RB
,/,
among/IN
the/DT
BioNLP/NN
community/NN
,/,
among/IN
dozens/NNS
of/IN
popularized/JJ
NER/NN
tools/NNS
,/,
including/VBG
tmChem/PRP
[/(
10/CD
]/)
,/,
DNorm/JJ
[/(
11/CD
]/)
,/,
GNormPlus/NNP
[/(
12/CD
]/)
,/,
and/CC
tmVar/JJ
[/(
13/CD
]/)
./.
====================
These/DT
were/VBD
regarded/VBN
as/IN
successful/JJ
representative/JJ
tools/NNS
for/IN
recognizing/VBG
chemicals/NNS
,/,
diseases/NNS
,/,
genes/NNS
,/,
and/CC
variations/NNS
./.
====================
In/IN
the/DT
meantime/NN
,/,
emergence/NN
of/IN
deep/JJ
learning/VBG
strategies/NNS
in/IN
NLP/NN
propelled/VBD
bio-NER/NN
dramatically/RB
,/,
by/IN
introducing/VBG
novel/JJ
and/CC
sophisticated/JJ
deep/NN
neural/JJ
network/NN
training/VBG
models/NNS
,/,
in/IN
the/DT
manner/NN
of/IN
classifier/NN
and/CC
word/NN
embedding/VBG
./.
====================
First/RB
,/,
deep/RB
learning/VBG
brought/VBN
a/DT
new/JJ
generation/NN
of/IN
neural/JJ
networks/NNS
as/IN
an/DT
effective/JJ
classifier/NN
,/,
i.e./FW
,/,
long/JJ
short-term/JJ
memory/JJ
(/(
LSTM/NN
)/)
neural/JJ
networks/NNS
;/:
Second/RB
,/,
deep/RB
learning/VBG
introduced/VBN
semantics/NNS
consideration/NN
,/,
like/IN
word/NN
embedding/VBG
,/,
as/IN
input/RB
,/,
and/CC
enhanced/VBD
the/DT
NER/NN
algorithms/NNS
./.
====================
For/IN
example/NN
,/,
Habibi/NNP
et/FW
al./FW
’/CD
s/NNS
work/NN
[/(
14/CD
]/)
was/VBD
typical/JJ
,/,
which/WDT
fully/RB
made/VBD
use/NN
of/IN
CRF/NN
,/,
LSTM/NN
,/,
and/CC
word/NN
embedding/VBG
,/,
to/TO
extract/NN
entities/VBZ
including/VBG
drugs/NNS
from/IN
text/JJ
,/,
and/CC
the/DT
results/NNS
of/IN
this/DT
work/NN
indicated/VBD
that/IN
deep-learning/VBG
methods/NNS
performed/VBN
better/RBR
than/IN
other/JJ
biomedical/JJ
NER/NN
methods/NNS
./.
====================
The/DT
attempts/NNS
of/IN
BioNLP/NN
community/NN
made/VBD
the/DT
massive/JJ
bioentity/NN
information/NN
retrieval/NN
more/RBR
accessible/JJ
./.
====================
As/IN
a/DT
user-friendly/RB
platform/NN
run/JJ
by/IN
NCBI/NN
,/,
PubTator/NN
[/(
15/CD
]/)
timely/RB
offered/VBD
the/DT
PubMed-scale/JJ
NER/NN
service/RB
to/TO
tag/NN
the/DT
above/JJ
entities/VBZ
./.
====================
By/IN
integrating/VBG
the/DT
tagged/JJ
entities/VBZ
of/IN
PubTator/NN
into/IN
the/DT
Stanford/NN
parsing/VBG
tree/CD
,/,
Percha/NN
and/CC
Altman/JJ
[/(
16/CD
]/)
grouped/VBD
PubMed/JJ
sentences/VBZ
into/IN
semantically-related/JJ
categories/NNS
,/,
to/TO
provide/VB
relations/NNS
between/IN
entities/VBZ
and/CC
pairs/NNS
,/,
for/IN
each/DT
sentence/NN
./.
====================
For/IN
instance/NN
,/,
six/CD
groups/NNS
of/IN
gene-chemical/JJ
pairs/NNS
were/VBD
carefully/RB
defined/VBN
in/IN
this/DT
work/NN
,/,
i.e./FW
,/,
drug/NN
target/NN
,/,
metabolism/NN
,/,
transport/VBP
,/,
inhibition/NN
,/,
agonism/NN
,/,
and/CC
antagonism/NN
./.
====================
Finally/RB
,/,
sophisticated/VBN
semantic/JJ
relations/NNS
were/VBD
mined/VBN
out/RP
,/,
such/JJ
as/IN
DDIs/NNS
,/,
and/CC
variations/NNS
in/IN
drug/NN
responses/NNS
./.
====================
Except/IN
PubMed/JJ
,/,
there/EX
were/VBD
several/JJ
text/NN
resources/VBZ
serving/VBG
for/IN
drug-related/JJ
knowledge/NN
discovery/NN
./.
====================
Online/RB
Mendelian/JJ
Inheritance/NN
in/IN
Man/JJ
(/(
OMIM/NN
,/,
https/VBZ
:/:
//www.omim.org//JJ
)/)
[/(
17/CD
]/)
for/IN
drug/NN
mechanism/NN
,/,
and/CC
ClinicalTrails.gov/NN
(/(
https/NNS
:/:
//www.clinicaltrials.gov//JJ
)/)
for/IN
drug/NN
usage/NN
./.
====================
OMIM/NN
,/,
a/DT
popular/JJ
knowledge/NN
base/NN
of/IN
human/JJ
genes/NNS
and/CC
genetic/JJ
disorders/NNS
,/,
offers/VBZ
enriched/JJ
text/RB
sets/NNS
for/IN
addressing/VBG
phenotypes/NNS
of/IN
mutated/VBN
genes/NNS
./.
====================
Wang/NNP
and/CC
Zhang/NNP
[/(
18/CD
]/)
manually/RB
curated/VBN
the/DT
functional/JJ
change/NN
mutations/NNS
type/NN
,/,
i.e./FW
,/,
loss/NN
of/IN
function/NN
(/(
LOF/NN
)/)
and/CC
gain/NN
of/IN
function/NN
(/(
GOF/NN
)/)
mutations/NNS
./.
====================
It/PRP
was/VBD
stated/VBN
that/DT
LOF/NN
and/CC
GOF/NN
recognition/NN
worked/VBD
for/IN
novel/JJ
drug/NN
discovery/NN
,/,
in/IN
terms/NNS
of/IN
core/NN
gene/NN
function/NN
change/NN
./.
====================
Wang/NNP
and/CC
Zhang/NNP
[/(
18/CD
]/)
hypothesized/VBN
that/IN
the/DT
“/NN
antagonist/NN
”/NN
chemical/JJ
maps/VBZ
to/TO
a/DT
targeted/VBN
gene/NN
with/IN
GOF/NN
,/,
while/IN
another/DT
“/NN
agonist/NN
”/NN
chemical/JJ
mapped/VBD
to/TO
the/DT
gene/NN
with/IN
LOF/NN
./.
====================
This/DT
hypothesis/NN
offered/VBD
a/DT
straightforward/JJ
rule/NN
for/IN
gene-drug/NN
pair/NN
filtering/VBG
./.
====================
Zhang/NNP
et/FW
al/JJ
./.
====================
[/(
19/CD
]/)
employed/VBN
OMIM/NN
and/CC
PubMed/JJ
to/TO
gather/RBR
GOF/NN
and/CC
LOF/NN
knowledge/NN
on/IN
the/DT
pathogenesis/NN
of/IN
antidiabetic/JJ
targets/NNS
,/,
finding/NN
nine/CD
drugs/NNS
for/IN
treating/VBG
diabetes/VBZ
./.
====================
Besides/RB
PubMed/JJ
text/RB
resources/VBZ
for/IN
published/VBN
papers/NNS
,/,
and/CC
OMIM/NN
for/IN
curated/JJ
heredity-centric/JJ
knowledge/NN
text/RB
,/,
ClinicalTrails.gov/NNP
is/VBZ
a/DT
representative/JJ
of/IN
an/DT
electronic/JJ
health/NN
record/NN
(/(
EHR/NN
)/)
text/RB
resource/NN
,/,
which/WDT
was/VBD
established/VBN
in/IN
1999/CD
[/(
20/CD
]/)
./.
====================
ClinicalTrails.gov/NN
contains/VBZ
various/JJ
information/NN
about/IN
medical/JJ
clinical/JJ
studies/NNS
in/IN
humans/NNS
,/,
and/CC
the/DT
open/JJ
access/NN
policy/NN
made/VBD
it/PRP
widely/RB
used/VBN
./.
====================
For/IN
example/NN
,/,
Su/NNP
and/CC
Sanger/NN
[/(
21/CD
]/)
extracted/VBN
serious/JJ
adverse/JJ
events/NNS
SAEs/NNS
data/NNS
from/IN
the/DT
text/NN
in/IN
ClinicalTrials.gov/NN
,/,
and/CC
ranked/VBD
drugs/NNS
by/IN
SAEs/NNS
data/NNS
,/,
to/TO
find/VB
those/DT
with/IN
the/DT
least/JJS
SAE/NN
./.
====================
Then/RB
,/,
new/JJ
drugs/NNS
could/MD
be/VB
predicted/VBN
according/VBG
to/TO
their/PRP$
SAEs/NNS
./.
====================
For/IN
example/NN
,/,
Xu/NNP
et/FW
al/JJ
./.
====================
[/(
22/CD
]/)
extracted/VBN
gene/NN
alterations/NNS
and/CC
identified/VBD
cancer/NN
treatment/NN
trials/NNS
by/IN
developing/VBG
a/DT
semi-automatic/JJ
framework/NN
on/IN
documents/NNS
at/IN
CliniclaTrails.gov/NN
./.
====================
In/IN
this/DT
research/NN
,/,
they/PRP
used/VBD
three/CD
steps/NNS
including/VBG
:/:
collect/JJ
candidate/NN
trials/NNS
about/RB
cancer/NN
treatment/NN
trials/NNS
,/,
score/RB
each/DT
candidate/NN
trials/NNS
,/,
and/CC
manually/RB
review/NN
trials/NNS
with/IN
lower/JJR
scores/VBZ
./.
====================
EHR/NN
data/NNS
is/VBZ
a/DT
popular/JJ
source/NN
information/NN
of/IN
clinical/JJ
and/CC
transnational/JJ
research/NN
for/IN
drug/NN
repurposing/VBG
./.
====================
Banda/NN
et/FW
al/JJ
./.
====================
[/(
23/CD
]/)
used/VBN
four/CD
sources/NNS
information/NN
from/IN
EHRs/NNS
including/VBG
public/JJ
database/NN
,/,
source/NN
of/IN
spontaneous/JJ
reports/NNS
,/,
literature/NN
and/CC
non-EHRs/NNS
DDIs/NNS
predication/NN
methods/NNS
to/TO
prioritize/VB
drug-/JJ
drug-event/JJ
association/NN
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
the/DT
abundant/JJ
clinical/JJ
information/NN
in/IN
EHR/NN
data/NNS
made/VBD
it/PRP
possible/JJ
to/TO
serve/VB
for/IN
various/JJ
precisional/JJ
medical/JJ
discovery/NN
./.
====================
Denny/RB
et/FW
al./FW
’/CD
s/NNS
PheWAS/NN
[/(
24/CD
]/)
combined/JJ
long/JJ
temporal/JJ
scale/NN
EHR/NN
data/NNS
with/IN
genomics/NNS
variation/NN
information/NN
,/,
and/CC
proposed/VBN
phenome-wide/NN
association/NN
study/NN
to/TO
trace/VB
core/NN
single/JJ
nucleotide/NN
polymorphisms/NNS
and/CC
disease/NN
trajectory/JJ
./.
====================
The/DT
emerging/VBG
cross/JJ
disciplinary/JJ
research/NN
based/VBN
on/IN
EHR/NN
as/IN
well/RB
propelled/VBN
the/DT
research/NN
issues/NNS
from/IN
Medical/JJ
Natural/JJ
Language/JJ
Processing/JJ
(/(
MedNLP/NN
)/)
[/(
25,26/CD
]/)
./.
====================
In/IN
all/DT
,/,
the/DT
development/NN
of/IN
large/JJ
data/NNS
resource/VBP
knowledge/NN
discovery/NN
unveiled/JJ
the/DT
following/VBG
tendencies/NNS
:/:
====================
(/(
1/CD
)/)
PubMed/JJ
is/VBZ
still/RB
the/DT
main/JJ
open/JJ
access/RB
resource/NN
for/IN
large/JJ
scale/JJ
resource/NN
,/,
meanwhile/JJ
,/,
lack/VBP
of/IN
other/JJ
text/JJ
resources/VBZ
with/IN
comparable/JJ
level/NN
and/CC
restriction/NN
of/IN
full/JJ
text/NN
access/RB
hinder/VBP
the/DT
development/NN
of/IN
large/JJ
scale/JJ
knowledge/NN
discovery/RB
for/IN
bio-text/JJ
miners/NNS
./.
====================
(/(
2/CD
)/)
After/IN
years/NNS
of/IN
development/NN
,/,
NER/NN
of/IN
biomedical/JJ
entities/VBZ
is/VBZ
not/RB
technical/JJ
headache/JJ
any/DT
longer/RBR
,/,
and/CC
make/VBP
it/PRP
possible/JJ
to/TO
run/JJ
comprehensive/JJ
knowledge/NN
extraction/NN
tasks/NNS
./.
====================
(/(
3/CD
)/)
As/IN
a/DT
result/NN
,/,
a/DT
combination/NN
of/IN
full/JJ
open/JJ
access/RB
to/TO
PubMed-wide/JJ
knowledge/NN
discovery/RB
and/CC
restricted/JJ
access/RB
EHR/NN
data/NNS
access/VBP
for/IN
drug/NN
knowledge/NN
is/VBZ
a/DT
main/JJ
research/NN
pat-/NN
tern/NN
in/IN
the/DT
next/JJ
decade/NN
./.
====================
Corpora/NN
and/CC
purposes/NNS
for/IN
drug-related/JJ
text/NN
mining/JJ
====================
Early/JJ
attempts/NNS
to/TO
apply/RB
BioNLP/NN
to/TO
knowledge/NN
discovery/NN
was/VBD
propelled/VBN
by/IN
the/DT
benchmark/NN
NLP/NN
dataset/NN
corpus/NN
./.
====================
A/DT
well-structured/JJ
corpus/NN
experiences/VBZ
a/DT
rigid/JJ
evaluation/NN
procedure/NN
that/DT
ensures/VBZ
its/PRP$
usability/NN
./.
====================
The/DT
steps/NNS
included/VBD
annotation/NN
guidelines/NNS
design/NN
,/,
annotation/NN
testing/NN
,/,
and/CC
inter-annotator/NN
agreement/NN
computation/NN
./.
====================
The/DT
pioneer/NN
work/NN
was/VBD
the/DT
corpus/NN
used/VBN
in/IN
DDIs/NNS
of/IN
DDI/NN
2011/CD
[/(
27/CD
]/)
,/,
DDI/NN
2013/CD
extraction/NN
challenge/NN
[/(
28/CD
]/)
,/,
and/CC
SemEval/JJ
2013/CD
task/NN
9/CD
[/(
29/CD
]/)
./.
====================
In/IN
early/JJ
attempts/NNS
,/,
Segura-Bedmar/JJ
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
used/VBN
POS-tagging/JJ
,/,
lemmatization/NN
,/,
and/CC
chunking/VBG
as/IN
features/NNS
of/IN
a/DT
shallow/JJ
linguistic/JJ
kernel/NN
method/NN
,/,
to/TO
perform/VB
DDI/NN
extraction/NN
./.
====================
To/TO
that/DT
end/NN
,/,
Bui/NNP
et/FW
al/JJ
./.
====================
[/(
30/CD
]/)
was/VBD
among/IN
dozens/NNS
of/IN
researchers/NNS
that/IN
attended/VBD
the/DT
DDI/NN
challenge/NN
,/,
which/WDT
manually/RB
created/VBD
292/CD
relevant/JJ
trigger/VBP
words/NNS
,/,
converted/VBD
sentences/VBZ
into/IN
semantic/JJ
structures/NNS
,/,
extracted/VBN
and/CC
fed/JJ
features/NNS
into/IN
a/DT
known/JJ
classifier/IN
support/VBP
vector/NN
machine/NN
(/(
SVM/NN
)/)
for/IN
DDI/NN
extraction/NN
./.
====================
Afterward/IN
,/,
Kim/NN
et/FW
al/JJ
./.
====================
[/(
31/CD
]/)
used/VBN
SVMs/NNS
,/,
as/IN
well/RB
as/IN
performing/JJ
DDI/NN
2013/CD
challenge/NN
,/,
but/CC
with/IN
richly/RB
combined/JJ
features/NNS
,/,
including/VBG
word/NN
features/NNS
,/,
word/NN
pair/NN
features/NNS
,/,
dependency/NN
graph/NN
features/NNS
,/,
and/CC
parse/JJ
tree/CD
features/NNS
./.
====================
Corpora/NN
design/NN
,/,
and/CC
its/PRP$
applications/NNS
,/,
gradually/RB
played/VBD
substantial/JJ
roles/NNS
in/IN
drug-related/JJ
knowledge/NN
discovery/NN
./.
====================
In/IN
2016/CD
,/,
for/IN
the/DT
purpose/NN
of/IN
oncology/NN
knowledge/NN
discovery/NN
,/,
Lee/NNP
et/FW
al/JJ
./.
====================
[/(
32/CD
]/)
created/VBD
a/DT
cancer/NN
and/CC
antitumor/JJ
Biomedical/JJ
entity/NN
Relation/NN
ONcology/NN
COrpus/NN
(/(
BRONCO/NN
)/)
,/,
which/WDT
focused/VBD
on/IN
the/DT
variant-centric/JJ
entities/VBZ
including/VBG
genes/NNS
,/,
diseases/NNS
,/,
drugs/NNS
,/,
and/CC
cell/NN
lines/NNS
./.
====================
Although/IN
BRONCO/NN
was/VBD
a/DT
disease-oriented/JJ
corpus/NN
,/,
it/PRP
focused/VBD
on/IN
drugs/NNS
,/,
and/CC
Lee/NNP
et/FW
al/JJ
./.
====================
[/(
33/CD
]/)
used/VBN
this/DT
corpus/NN
to/TO
evaluate/VB
and/CC
develop/VBP
a/DT
mutation-gene-drug/NN
discovery/NN
pipeline/NN
./.
====================
Focus/DT
on/IN
adverse/JJ
reactions/NNS
(/(
ADRs/NNS
)/)
or/CC
side/JJ
effects/NNS
on/IN
drugs/NNS
has/VBZ
attracted/VBN
the/DT
attention/NN
of/IN
corpus/NN
designers/VBZ
./.
====================
In/IN
that/DT
regard/NN
,/,
Fang/NN
et/FW
al/JJ
./.
====================
[/(
34/CD
]/)
illustrated/JJ
proper/JJ
terminology/NN
discrimination/NN
upon/IN
ADR/NN
corpus/NN
design/NN
./.
====================
A/DT
recent/JJ
ADR-oriented/JJ
corpus/NN
was/VBD
created/VBN
by/IN
an/DT
NCBI/NN
team/JJ
Demner-Fushman/JJ
et/FW
al/JJ
./.
====================
[/(
35/CD
]/)
,/,
i.e./FW
,/,
Text/JJ
Analysis/NN
Conference/NN
(/(
TAC/NN
)/)
2017/CD
drug/NN
labels/NNS
corpus/NN
,/,
which/WDT
annotated/VBD
labels/NNS
of/IN
two/CD
hundred/JJ
Food/NN
and/CC
Drug/NN
Administration/NN
approved/JJ
drugs/NNS
./.
====================
The/DT
mentioned/JJ
topics/NNS
they/PRP
annotated/VBD
covered/VBD
“/CD
severity/NN
,/,
”/NNP
“/CD
drug/NN
class/NN
,/,
”/NNP
“/CD
adverse/JJ
reaction/NN
,/,
”/NNP
etc./FW
,/,
which/WDT
were/VBD
fairly/RB
usable/JJ
for/IN
ADR/NN
evaluation/NN
of/IN
drugs/NNS
./.
====================
ADR/NN
extraction/NN
was/VBD
among/IN
the/DT
successfully/RB
held/RB
tasks/VBZ
of/IN
TAC/NN
2017/CD
and/CC
2018/CD
[/(
36/CD
]/)
,/,
and/CC
afterwards/IN
the/DT
same/JJ
NCBI/NN
team/JJ
constructed/VBN
MEDIQA/NN
challenge/NN
,/,
an/DT
Association/NN
for/IN
Computational/JJ
Linguistics–community/JJ
challenge/NN
for/IN
the/DT
question/NN
entailment/JJ
of/IN
medical/JJ
records/NNS
[/(
37/CD
]/)
which/WDT
expanded/VBD
the/DT
drug-related/JJ
ADR/NN
extraction/NN
to/TO
wider/RBR
clinical/JJ
scenarios/NNS
,/,
also/RB
known/VBN
as/IN
MedNLP/NN
./.
====================
Another/DT
focus/NN
on/IN
drug-related/JJ
corpus/NN
construction/NN
is/VBZ
on/IN
drug/NN
repurposing/VBG
./.
====================
Until/IN
now/RB
,/,
the/DT
corpus/NN
working/VBG
on/IN
drug/NN
repurposing/VBG
was/VBD
rare/JJ
./.
====================
Recent/JJ
progress/NN
came/VBD
from/IN
Wang/NNP
et/FW
al./FW
’/CD
s/NNS
work/NN
[/(
38/CD
]/)
,/,
which/WDT
designed/VBD
an/DT
“/NN
active/JJ
gene/NN
annotation/NN
corpus/NN
(/(
AGAC/NN
)/)
”/CD
to/TO
cultivate/VB
functional/JJ
change/NN
of/IN
mutated/VBN
genes/NNS
./.
====================
AGAC/NN
aimed/VBD
to/TO
capture/JJ
LOF-/NN
or/CC
GOF-mutated/JJ
genes/NNS
,/,
and/CC
made/VBD
it/PRP
possible/JJ
to/TO
find/VB
“/FW
agonist/NN
vs./CC
LOF/NN
”/CD
and/CC
“/FW
antagonist/NN
vs./CC
GOF/NN
”/CD
pairs/NNS
for/IN
“/JJ
drug/NN
vs./CC
gene./FW
”/CD
This/DT
was/VBD
a/DT
nice/RB
addition/NN
to/TO
a/DT
mutation-centric/JJ
corpus/FW
for/IN
the/DT
purpose/NN
of/IN
drug/NN
repurposing/VBG
[/(
38/CD
]/)
./.
====================
The/DT
development/NN
of/IN
drug-oriented/JJ
corpora/NN
design/NN
showed/VBD
clear/JJ
tendency/NN
as/IN
below/IN
./.
====================
(/(
1/CD
)/)
DDIs/NNS
were/VBD
a/DT
key/JJ
focus/NN
in/IN
corpora/NN
design/NN
,/,
and/CC
the/DT
DDI/NN
corpus/NN
has/VBZ
long/JJ
been/VBN
a/DT
tradition/NN
in/IN
drug-related/JJ
corpus/NN
construction/NN
./.
====================
(/(
2/CD
)/)
Disease-oriented/JJ
corpora/NN
covered/VBD
drug-/JJ
related/JJ
knowledge/NN
curation/NN
,/,
which/WDT
served/VBD
directly/RB
to/TO
specific/JJ
disease/NN
and/CC
focused/VBD
on/IN
tumors/NNS
as/IN
targets/NNS
./.
====================
(/(
3/CD
)/)
Drug-related/JJ
ADR/NN
or/CC
side/JJ
effect/NN
information/NN
was/VBD
a/DT
focus/JJ
in/IN
corpora/NN
design/NN
which/WDT
served/VBD
for/IN
drug/NN
effect/NN
,/,
and/CC
as/IN
well/RB
led/VBD
to/TO
expanded/VBN
attention/NN
in/IN
medical/JJ
and/CC
clinical/JJ
applications/NNS
./.
====================
(/(
4/CD
)/)
Mutation-centric/JJ
corpus/NN
was/VBD
a/DT
novel/JJ
addition/NN
to/TO
the/DT
drug-related/JJ
corpora/NN
,/,
which/WDT
was/VBD
aimed/VBN
to/TO
the/DT
application/NN
of/IN
drug/NN
repurposing/VBG
./.
====================
Heterogeneous/JJ
data/NNS
for/IN
drug-related/JJ
knowledge/NN
discovery/NN
====================
Unlike/IN
traditional/JJ
text/NN
data/NNS
,/,
heterogeneous/JJ
data/NNS
is/VBZ
generally/RB
non-scientific/JJ
text/NN
,/,
like/IN
so/RB
cial/JJ
media/NNS
and/CC
various/JJ
omics/NNS
data/NNS
,/,
including/VBG
genomic/JJ
or/CC
proteomic/JJ
data/NNS
./.
====================
While/IN
the/DT
non-scientific/JJ
text/RB
enhanced/VBD
research/NN
studies/NNS
,/,
with/IN
social/JJ
concerns/VBZ
such/JJ
as/IN
drug/NN
abuse/IN
,/,
drug/NN
misuse/NN
,/,
and/CC
drug/NN
safety/NN
,/,
the/DT
various/JJ
omics/NNS
data/NNS
achieved/VBD
success/JJ
under/IN
the/DT
collaboration/NN
of/IN
BioNLP/NN
and/CC
bioinformatics/NNS
community/NN
./.
====================
Just/RB
like/IN
Twitter/JJ
served/VBD
well/RB
for/IN
drug/NN
prescription/NN
and/CC
drug/NN
abuse/IN
[/(
39/CD
]/)
,/,
social/JJ
media/NNS
allowed/VBD
fast/JJ
tracking/VBG
of/IN
public/JJ
opinion/NN
,/,
and/CC
became/VBD
popular/JJ
resources/VBZ
for/IN
adverse/JJ
drug/NN
reaction/NN
mining/VBG
[/(
40,41/CD
]/)
,/,
drug/NN
misuse/NN
[/(
42/CD
]/)
,/,
drug/NN
safety/NN
[/(
43/CD
]/)
,/,
etc/JJ
./.
====================
It/PRP
was/VBD
worth/DT
noting/VBG
that/DT
social/JJ
media/NNS
texts/NNS
were/VBD
mainly/RB
integrated/VBN
into/IN
research/NN
with/IN
social/JJ
issue/NN
topics/NNS
,/,
instead/RB
of/IN
drug/NN
knowledge/NN
in/IN
the/DT
molecular/JJ
level/NN
./.
====================
With/IN
emergence/NN
of/IN
multi-omics/NNS
data/NNS
,/,
the/DT
integration/NN
of/IN
text/JJ
data/NNS
with/IN
genome/NN
,/,
or/CC
protome/JJ
data/NNS
attracted/VBD
attention/NN
from/IN
a/DT
cross/JJ
disciplinary/JJ
view/NN
,/,
for/IN
the/DT
purpose/NN
of/IN
drug-gene/JJ
linking/VBG
discovery/NN
./.
====================
Early/JJ
attempts/NNS
of/IN
linking/VBG
chemical/JJ
to/TO
candidate/VB
genes/NNS
was/VBD
performed/VBN
in/IN
late/JJ
2000s/NN
by/IN
Li/NN
et/FW
al/JJ
./.
====================
[/(
44/CD
]/)
,/,
who/WP
showed/VBD
a/DT
significant/JJ
combination/NN
of/IN
traditional/JJ
bioinformatics/NNS
and/CC
BioNLP/NN
approaches/NNS
./.
====================
This/DT
study/NN
used/VBD
Online/NN
Predicted/JJ
Human/JJ
Interaction/NN
Database/NN
(/(
OPHID/NN
)/)
,/,
a/DT
predicted/VBN
protein/NN
association/NN
network/NN
database/NN
,/,
to/TO
obtain/VB
protein/NN
networks/NNS
of/IN
Alzheimer/NN
disease/NN
,/,
retrieved/VBD
from/IN
disease-drug-protein/JJ
links/NNS
from/IN
PubMed/JJ
,/,
and/CC
formed/VBD
a/DT
reliable/JJ
connectivity/NN
map/VBP
./.
====================
In/IN
most/JJS
cases/NNS
,/,
multi-omics/NNS
data/NNS
integration/NN
led/VBD
to/TO
indirect/VB
link/NN
discovery/NN
between/IN
drugs/NNS
and/CC
their/PRP$
targeted/VBN
proteins/NNS
or/CC
candidate/NN
loci/NNS
./.
====================
Zhang/NNP
et/FW
al/JJ
./.
====================
[/(
45/CD
]/)
obtained/VBN
a/DT
colorectal/JJ
cancer-related/JJ
gene/NN
list/NN
by/IN
text/JJ
mining/JJ
from/IN
PubMed/JJ
and/CC
then/RB
integrated/VBN
genomics/NNS
data/NNS
and/CC
proteomics/NNS
data/NNS
to/TO
identify/VB
the/DT
more/RBR
risky/NN
loci/NNS
associated/VBN
with/IN
colorectal/JJ
cancer/NN
./.
====================
Barupal/JJ
et/FW
al/JJ
./.
====================
[/(
46/CD
]/)
investigated/VBD
metabolic/JJ
genes/NNS
as/IN
therapeutic/JJ
targets/NNS
in/IN
breast/NN
tumors/NNS
by/IN
using/VBG
multi-omics/NNS
data/NNS
and/CC
text/NN
mining/JJ
./.
====================
Meanwhile/DT
,/,
Long/JJ
et/FW
al/JJ
./.
====================
[/(
47/CD
]/)
identified/VBD
and/CC
validated/VBD
oncogenic/JJ
biomarkers/NNS
of/IN
pancreatic/JJ
cancer/NN
,/,
through/IN
integrative/JJ
text/NN
mining/JJ
and/CC
omics-based/VBD
translational/JJ
modelling/VBG
./.
====================
Such/JJ
progress/VBP
also/RB
reflects/VBZ
the/DT
mainstream/JJ
data/NNS
fusion/NN
research/NN
idea/NN
within/IN
the/DT
bioinformatics/NNS
community/NN
./.
====================
To/TO
conclude/VB
,/,
the/DT
availability/NN
of/IN
the/DT
heterogeneous/JJ
data/NNS
propelled/VBD
drug-related/JJ
knowledge/NN
discovery/NN
both/CC
in/FW
social/JJ
and/CC
bioinformatics/NNS
domains/NNS
./.
====================
(/(
1/CD
)/)
Social/JJ
media/NNS
data/NNS
became/VBD
an/DT
exclusively/RB
important/JJ
resources/NNS
for/IN
collecting/JJ
public/JJ
opinion/NN
,/,
helping/VBG
to/TO
resolve/VB
several/JJ
drug-related/JJ
topics/NNS
,/,
such/JJ
as/IN
drug/NN
safety/NN
,/,
drug/NN
usage/NN
,/,
or/CC
drug/NN
side/JJ
effects/NNS
./.
====================
(/(
2/CD
)/)
Integration/NN
of/IN
text/JJ
data/NNS
with/IN
multi-omics/NNS
data/NNS
became/VBD
a/DT
tendency/NN
upon/IN
drug-gene/JJ
linking/VBG
or/CC
therapeutic/JJ
target/NN
discovery/NN
,/,
and/CC
huge/JJ
text/RB
data/NNS
was/VBD
regarded/VBN
as/IN
one/CD
member/NN
of/IN
omics/NNS
data/NNS
from/IN
the/DT
view/NN
of/IN
the/DT
bioinformatics/NNS
community/NN
./.
====================
Matrix/NN
or/CC
tensor/JJ
decomposition/NN
methods/NNS
for/IN
drug-related/JJ
knowledge/NN
discovery/NN
====================
Matrix/JJ
factorization/NN
or/CC
decomposition/NN
are/VBP
important/JJ
techniques/NNS
for/IN
extracting/VBG
information/NN
from/IN
a/DT
matrix/NN
or/CC
a/DT
tensor/JJ
[/(
48/CD
]/)
./.
====================
Basically/RB
,/,
a/DT
matrix/NN
A∈/NN
Rm×n/NN
refers/VBZ
to/TO
a/DT
m/NN
×/CD
n/NN
data/NNS
array/NN
,/,
which/WDT
is/VBZ
suitable/JJ
for/IN
storing/VBG
and/CC
linking/VBG
two/CD
entities/VBZ
./.
====================
Meanwhile/DT
,/,
an/DT
M-way/NN
tensor/NN
Rn1/NN
×n2/NN
×···×nM/NN
provides/VBZ
a/DT
higher/JJR
ordered/VBN
structure/NN
,/,
which/WDT
is/VBZ
capable/JJ
of/IN
storing/VBG
M/NN
different/JJ
kinds/NNS
of/IN
entities/VBZ
./.
====================
The/DT
computational/JJ
decomposition/NN
(/(
sometimes/RB
called/VBN
factorization/NN
)/)
result/VBP
of/IN
a/DT
matrix/NN
or/CC
a/DT
tensor/JJ
led/VBD
to/TO
a/DT
so-called/JJ
low/JJ
rank/NN
approximation/NN
of/IN
the/DT
original/JJ
structure/NN
,/,
and/CC
made/VBD
a/DT
basis/NN
for/IN
novel/JJ
link/NN
discovery/NN
./.
====================
If/IN
compared/VBN
with/IN
great/JJ
amount/NN
and/CC
various/JJ
patterns/NNS
of/IN
BioNLP/NN
research/NN
on/IN
drug-related/JJ
knowledge/NN
discovery/NN
,/,
the/DT
research/NN
of/IN
matrix/NN
or/CC
tensor/JJ
decomposition/NN
was/VBD
comparatively/RB
less/RBR
,/,
and/CC
more/RBR
topic-specific/JJ
./.
====================
In/IN
general/JJ
,/,
the/DT
adaptable/JJ
data/NNS
structure/NN
made/VBD
it/PRP
possible/JJ
to/TO
illustrate/VB
higher/JJR
order/NN
links/NNS
,/,
while/IN
the/DT
lower/JJR
rank/VBP
approximation/NN
made/VBD
it/PRP
a/DT
suitable/JJ
one/CD
for/IN
novel/JJ
link/NN
discovery/NN
./.
====================
A/DT
comprehensive/JJ
review/NN
of/IN
mathematical/JJ
illustration/NN
of/IN
the/DT
matrix/NN
decomposition/NN
(/(
“/LS
also/RB
known/VBN
as/IN
matrix/NN
factorization/NN
”/NNP
)/)
by/IN
Wang/NNP
and/CC
Zhang/NNP
’/NNP
s/NNS
work/NN
[/(
49/CD
]/)
listed/VBN
basic/JJ
notations/NNS
,/,
definitions/NNS
and/CC
detailed/JJ
ideas/IN
,/,
while/IN
Kolda/NN
and/CC
Bader/NN
[/(
50/CD
]/)
provided/VBD
another/DT
one/CD
for/IN
tensor/JJ
decomposition/NN
,/,
including/VBG
the/DT
classic/JJ
CANDE-COMP/PARAFAC/NN
(/(
CP/NN
)/)
and/CC
Tucker/NN
decomposition/NN
./.
====================
To/TO
trace/VB
the/DT
rapid/JJ
development/NN
of/IN
knowledge/NN
inference/IN
in/IN
the/DT
years/NNS
of/IN
knowledge/NN
graph/NN
,/,
Nickel/NN
et/FW
al./FW
’/CD
s/NNS
RESCAL/NN
algorithm/NN
[/(
51/CD
]/)
made/VBD
good/JJ
use/NN
of/IN
tensor/JJ
structure/NN
for/IN
triple/JJ
knowledge/NN
./.
====================
In/IN
addition/NN
,/,
Nimishakavi/NNP
’/CD
s/NNS
series/NN
work/NN
on/IN
higher/JJR
order/NN
relation/NN
schema/NN
[/(
52,53/CD
]/)
,/,
and/CC
side/JJ
information/NN
integration/NN
,/,
were/VBD
representative/JJ
issues/NNS
in/IN
higher/JJR
order/NN
link/NN
discovery/NN
and/CC
multi-resource/JJ
data/NNS
fusion/NN
./.
====================
Since/IN
this/DT
review/NN
is/VBZ
mainly/RB
for/IN
concluding/VBG
research/NN
on/IN
drug-related/JJ
knowledge/NN
discovery/NN
,/,
the/DT
following/VBG
section/NN
reviews/VBZ
the/DT
matrix/NN
and/CC
tensor/NN
level/NN
decomposition/NN
and/CC
applications/NNS
on/IN
drug/NN
,/,
respectively/RB
./.
====================
Matrix/NN
decomposition/NN
method/NN
====================
Matrix/JJ
decomposition/NN
obtains/NNS
a/DT
sum/NN
of/IN
lower-rank/JJ
matrices/NNS
,/,
and/CC
then/RB
models/NNS
a/DT
small/JJ
number/NN
of/IN
factors/NNS
[/(
54/CD
]/)
./.
====================
A/DT
matrix/NN
decomposition/NN
models/NNS
known/VBN
associations/NNS
,/,
which/WDT
predicts/VBZ
novel/JJ
drug/NN
indications/NNS
./.
====================
In/IN
2013/CD
,/,
Zheng/JJ
et/FW
al/JJ
./.
====================
[/(
55/CD
]/)
predicted/VBN
new/JJ
drug-target/NN
interactions/NNS
by/IN
using/VBG
collaborative/JJ
matrix/NN
factorization/NN
./.
====================
In/IN
their/PRP$
work/NN
,/,
three/CD
different/JJ
datasets/NNS
,/,
such/JJ
as/IN
drug-target/JJ
interactions/NNS
,/,
DDIs/NNS
,/,
and/CC
target-target/NN
interactions/NNS
were/VBD
input/RB
to/TO
build/JJ
three/CD
matrices/NNS
./.
====================
After/IN
matrix/NN
factorization/NN
,/,
two/CD
low-rank/JJ
matrices/NNS
were/VBD
obtained/VBN
,/,
which/WDT
approximate/VBP
to/TO
the/DT
known/JJ
drug-target/JJ
interaction/NN
matrix/NN
,/,
and/CC
novel/JJ
relationship/NN
predictions/NNS
were/VBD
able/JJ
to/TO
perform/VB
by/IN
the/DT
new/JJ
number/NN
in/IN
the/DT
approximate/JJ
matrix/NN
./.
====================
In/IN
this/DT
research/NN
,/,
three/CD
kinds/NNS
of/IN
data/NNS
such/JJ
as/IN
drug-target/JJ
interaction/NN
,/,
drug/NN
similarity/NN
,/,
and/CC
target/NN
similarity/NN
were/VBD
input/RB
into/IN
the/DT
three/CD
matrices/NNS
separately/RB
./.
====================
Similarly/RB
,/,
Liu/NNP
et/FW
al./FW
’/CD
s/NNS
work/NN
[/(
56/CD
]/)
presented/VBN
an/DT
integrated/JJ
framework/NN
to/TO
create/VB
new/JJ
therapeutic/JJ
associations/NNS
between/IN
drug-drug/NN
,/,
drug-disease/NN
,/,
and/CC
disease-disease/NN
by/IN
matrix/NN
decomposition/NN
./.
====================
Zhang/NNP
et/FW
al/JJ
./.
====================
[/(
57/CD
]/)
proposed/VBN
two/CD
projections/NNS
including/VBG
low-dimensional/JJ
drug/NN
projection/NN
and/CC
disease/NN
projection/NN
matrix/NN
,/,
and/CC
utilized/VBD
them/PRP
to/TO
factorize/VB
the/DT
drug-disease/NN
matrix/NN
./.
====================
Dai/NN
et/FW
al/JJ
./.
====================
[/(
58/CD
]/)
used/VBN
three/CD
interaction/NN
data/NNS
,/,
including/VBG
drug-disease/NN
,/,
disease-gene/JJ
,/,
and/CC
drug-gene/NN
interactions/NNS
,/,
to/TO
predict/VB
drug-disease/NN
association/NN
./.
====================
In/IN
their/PRP$
work/NN
,/,
they/PRP
clustered/VBD
genes/NNS
by/IN
using/VBG
gene-drug/NN
interactions/NNS
and/CC
gene-disease/NN
interactions/NNS
,/,
respectively/RB
,/,
and/CC
two/CD
different/JJ
clustering/NN
results/NNS
consisted/VBD
of/IN
two/CD
axes/NNS
of/IN
matrix/NN
./.
====================
After/IN
matrix/NN
factorization/NN
,/,
the/DT
novel/JJ
relations/NNS
between/IN
the/DT
clusters/NNS
were/VBD
predicted/VBN
./.
====================
Through/IN
tracing/VBG
backing/JJ
to/TO
the/DT
corresponding/JJ
disease/NN
and/CC
drug/NN
of/IN
the/DT
clusters/NNS
,/,
newly/RB
drug-disease/NN
relations/NNS
were/VBD
obtained/VBN
./.
====================
Tensor/NN
decomposition/NN
method/NN
====================
Tensor/NN
decomposition/NN
appeared/VBD
early/JJ
in/IN
1927/CD
[/(
59/CD
]/)
and/CC
emerged/VBN
into/IN
computer/NN
science/NN
applications/NNS
in/IN
the/DT
2000s/NN
./.
====================
Tensors/NNS
incorporate/VBP
a/DT
multidimensional/JJ
array/NN
of/IN
numerical/JJ
data/NNS
and/CC
are/VBP
applied/VBN
to/TO
various/JJ
machine-learning/JJ
tasks/NNS
[/(
48/CD
]/)
./.
====================
Similar/JJ
to/TO
matrix/NN
factorization/NN
,/,
tensor/NN
decomposition/NN
extracted/VBN
a/DT
low/JJ
rank/NN
approximation/NN
of/IN
drug/NN
data/NNS
,/,
while/IN
withholding/VBG
more/RBR
complex/NN
data/NNS
structure/NN
./.
====================
To/TO
that/DT
end/NN
,/,
Ho/NN
et/FW
al/JJ
./.
====================
[/(
60/CD
]/)
utilized/VBD
tensor/NN
decomposition/NN
,/,
in/IN
an/DT
unsupervised/JJ
manner/NN
,/,
for/IN
EHR/NN
data/NNS
,/,
and/CC
extracted/VBN
candidate/NN
phenotype/NN
generation/NN
through/IN
checking/VBG
interactions/NNS
of/IN
diagnoses/NNS
and/CC
drugs/NNS
among/IN
patients/NNS
./.
====================
Arany/DT
et/FW
al/JJ
./.
====================
[/(
61/CD
]/)
similarly/RB
used/VBN
tensor/JJ
decomposition/NN
to/TO
infer/VB
drug-protein/NN
interaction/NN
types/NNS
:/:
competitive/JJ
or/CC
non-competitive/JJ
./.
====================
This/DT
was/VBD
a/DT
novel/JJ
idea/NN
in/IN
this/DT
research/NN
to/TO
design/VB
a/DT
3-way/JJ
tensor/NN
with/IN
cell/NN
ijk/NN
represented/VBN
inhibition/NN
of/IN
the/DT
j-th/NN
protein/NN
with/IN
i-th/DT
drug/NN
for/IN
the/DT
k-th/NN
given/VBN
inhibition/NN
measure/VBP
,/,
and/CC
to/TO
decompose/VB
the/DT
tensor/JJ
by/IN
using/VBG
side/JJ
information/NN
of/IN
chemical/JJ
features/NNS
./.
====================
Basically/RB
,/,
it/PRP
was/VBD
a/DT
natural/JJ
idea/NN
to/TO
incorporate/VB
various/JJ
drug-related/JJ
information/NN
into/IN
the/DT
axes/NNS
of/IN
a/DT
tensor/JJ
,/,
and/CC
achieve/VBP
an/DT
imaginary/JJ
knowledge/NN
structure/NN
./.
====================
Khan/NN
et/FW
al/JJ
./.
====================
[/(
62/CD
]/)
proposed/VBN
structural/JJ
toxicogenomics/NNS
complex/NN
tensors/NNS
by/IN
creating/VBG
structure/NN
matrices/VBZ
with/IN
drugs/NNS
and/CC
structural/JJ
descriptors/NNS
,/,
respectively/RB
,/,
a/DT
gene/NN
tensor/NN
for/IN
diseases/NNS
,/,
and/CC
post-treatment/JJ
gene/NN
expression/NN
,/,
and/CC
a/DT
toxicity/NN
tensor/NN
with/IN
drug/NN
toxicity/NN
measurements/NNS
./.
====================
Decomposition/NN
of/IN
the/DT
complex/NN
tensors/NNS
led/VBD
to/TO
predictions/NNS
of/IN
toxicity/NN
of/IN
unseen/JJ
drugs/NNS
./.
====================
Afterward/IN
,/,
Taguchi/NN
et/FW
al/JJ
./.
====================
[/(
4/CD
]/)
performed/VBN
a/DT
series/NN
of/IN
studies/NNS
on/IN
identified/VBN
candidate/NN
drugs/NNS
,/,
especially/RB
drugs/NNS
for/IN
heart/NN
failure/NN
[/(
63/CD
]/)
,/,
by/IN
integrating/VBG
gene/NN
expression/NN
data/NNS
into/IN
a/DT
tensor/JJ
decomposition/NN
model/NN
./.
====================
Unlike/IN
linking/VBG
drug-protein/NN
,/,
drug-toxicity/NN
,/,
or/CC
drug-disease/NN
pairs/NNS
,/,
linking/VBG
drug-consumer/NN
led/VBD
to/TO
different/JJ
applications/NNS
,/,
like/IN
drug/NN
recommendations/NNS
./.
====================
Wang/NN
et/FW
al/JJ
./.
====================
[/(
64/CD
]/)
likewise/JJ
designed/VBN
a/DT
3-way/NN
tensor/NN
with/IN
“/NN
user/NN
,/,
”/NNP
“/CD
drug/NN
”/NN
and/CC
“/NN
label/NN
,/,
”/NNP
and/CC
constructed/VBD
a/DT
precise/JJ
drug/NN
recommendation/NN
model/NN
./.
====================
The/DT
above/JJ
methods/NNS
mainly/RB
fulfilled/JJ
tensor/NN
axes/NNS
with/IN
various/JJ
drug-related/JJ
domain/NN
data/NNS
like/IN
gene/NN
expression/NN
or/CC
chemical/JJ
features/NNS
,/,
and/CC
then/RB
a/DT
novel/JJ
link/NN
discovery/NN
was/VBD
mined/VBN
out/IN
from/IN
the/DT
decomposed/VBN
tensor/NN
./.
====================
Meanwhile/DT
,/,
a/DT
hybrid/NN
strategy/NN
of/IN
BioNLP/NN
and/CC
tensor/NN
decompostion/NN
came/VBD
from/IN
Zhou/NNP
et/FW
al/JJ
./.
====================
[/(
65/CD
]/)
,/,
who/WP
used/VBD
AGAC/NN
corpus/NN
[/(
38/CD
]/)
as/IN
a/DT
training/JJ
set/NN
to/TO
perform/VB
OMIM-wide/NN
text/RB
mining/JJ
,/,
and/CC
predict/VBP
novel/JJ
higher/JJR
order/NN
links/NNS
among/IN
five/CD
entities/VBZ
,/,
including/VBG
genes/NNS
,/,
mutations/NNS
,/,
functions/VBZ
,/,
diseases/NNS
,/,
and/CC
functional/JJ
changes/NNS
./.
====================
In/IN
this/DT
work/NN
,/,
new/JJ
nonzero/JJ
cells/NNS
in/IN
the/DT
decomposed/VBN
tensors/NNS
were/VBD
treated/VBN
as/IN
novel/JJ
links/NNS
,/,
among/IN
five/CD
entities/VBZ
,/,
and/CC
infer/VBP
the/DT
functional/JJ
change/NN
of/IN
a/DT
mutated/VBN
gene/NN
./.
====================
Finally/RB
,/,
agonist/antagonist/NN
drug/NN
information/NN
was/VBD
extracted/VBN
from/IN
DrugBank/NN
[/(
66/CD
]/)
,/,
and/CC
applied/VBD
to/TO
help/VB
linking/VBG
“/CD
agonist/NN
vs./CC
LOF/NN
”/CD
and/CC
“/NN
antagonist/NN
vs./CC
GOF/NN
”/CD
pairs/NNS
,/,
for/IN
the/DT
purpose/NN
of/IN
drug/NN
repurposing/VBG
./.
====================
Research/NN
pattern/NN
of/IN
novel/JJ
drug-related/JJ
knowledge/NN
link/NN
discovery/NN
in/IN
the/DT
form/NN
of/IN
matrix/NN
or/CC
tensor/JJ
decomposition/NN
====================
Among/IN
the/DT
above/JJ
research/NN
studies/NNS
,/,
the/DT
characteristics/NNS
of/IN
matrix/NN
or/CC
tensor/JJ
decomposition/NN
method/NN
enabled/VBD
investigators/NNS
to/TO
input/VB
multiple/JJ
data/NNS
,/,
and/CC
thus/RB
provide/VBP
more/RBR
comprehensive/JJ
information/NN
for/IN
prediction/NN
,/,
which/WDT
may/MD
elevate/VB
knowledge/NN
prediction/NN
accuracy/NN
./.
====================
The/DT
research/NN
tendency/NN
of/IN
matrix/NN
or/CC
tensor/JJ
decomposition/NN
on/IN
drug-related/JJ
knowledge/NN
discovery/NN
is/VBZ
listed/VBN
below/IN
./.
====================
(/(
1/CD
)/)
Matrix/NN
or/CC
Tensors/NNS
are/VBP
natural/JJ
data/NNS
structures/NNS
to/TO
contain/VB
multiple/JJ
arrays/NNS
of/IN
drug-related/JJ
entries/VBZ
./.
====================
Paired/JJ
knowledge/NN
entries/VBZ
are/VBP
mapped/VBN
into/IN
a/DT
matrix/NN
element/NN
,/,
such/JJ
as/IN
a/DT
drug-target/JJ
,/,
drug-drug/NN
pair/NN
,/,
while/IN
three/CD
linked/VBN
entities/VBZ
are/VBP
mapped/VBN
into/IN
a/DT
cell/NN
in/IN
tensor/JJ
,/,
such/JJ
as/IN
“/RB
drug/NN
”/NN
,/,
“/NNP
user/NN
,/,
”/NNP
and/CC
“/FW
label/JJ
,/,
”/NNP
in/IN
drug/NN
recommendations/NNS
./.
====================
Furthermore/RB
,/,
higher/JJR
order/NN
links/NNS
are/VBP
mapped/VBN
into/IN
higher/JJR
order/NN
tensors/NNS
./.
====================
(/(
2/CD
)/)
Generally/RB
,/,
novel/JJ
link/NN
discovery/NN
is/VBZ
inferred/VBN
from/IN
the/DT
novel/JJ
nonzero/NN
cells/NNS
in/IN
the/DT
decomposed/VBN
matrix/NN
or/CC
tensor/JJ
./.
====================
Methods/NNS
differ/VBP
according/VBG
to/TO
the/DT
chosen/NN
decomposition/NN
algorithm/NN
./.
====================
For/IN
example/NN
,/,
a/DT
new/JJ
link/NN
is/VBZ
inferred/VBN
from/IN
a/DT
core/NN
tensor/NN
after/IN
decomposition/NN
in/IN
a/DT
RESCAL-based/JJ
tensor/NN
decomposition/NN
,/,
while/IN
a/DT
nonzero/JJ
cell/NN
in/IN
the/DT
approximated/JJ
tensor/NN
counts/NNS
as/IN
a/DT
novel/JJ
link/NN
in/IN
a/DT
CP/NN
decomposition/NN
./.
====================
(/(
3/CD
)/)
Three/CD
way/NN
tensors/NNS
were/VBD
the/DT
most/JJS
popular/JJ
choice/NN
in/IN
the/DT
knowledge/NN
inference/NN
applications/NNS
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
,/,
a/DT
3-way/NN
tensor/NN
is/VBZ
favored/VBN
more/RBR
in/IN
a/DT
triple/JJ
data/NNS
structure/NN
than/IN
that/DT
in/IN
two/CD
matrices/NNS
,/,
thus/RB
making/VBG
it/PRP
convenient/JJ
for/IN
high-order/JJ
link/NN
data/NNS
representation/NN
./.
====================
It/PRP
is/VBZ
straightforward/JJ
to/TO
claim/NN
that/DT
a/DT
M-way/NN
tensor/NN
can/MD
provide/VB
a/DT
natural/JJ
data/NNS
structure/NN
to/TO
store/VB
higher-order/JJ
links/NNS
mentioning/VBG
M/NN
entities/VBZ
./.
====================
However/RB
,/,
the/DT
higher/JJR
the/DT
reach/NN
of/IN
the/DT
level/NN
,/,
the/DT
more/RBR
sparse/JJ
the/DT
tensor/NN
is/VBZ
./.
====================
This/DT
creates/VBZ
a/DT
computational/JJ
bottleneck/NN
./.
====================
(/(
4/CD
)/)
Knowledge/NN
inference/RB
algorithms/NNS
such/JJ
as/IN
jointly/RB
decomposed/VBD
matrices/NNS
and/CC
tensors/NNS
,/,
bring/VBG
the/DT
data/NNS
fusion/NN
idea/NN
into/IN
the/DT
matrix/NN
or/CC
tensor/JJ
decomposition/NN
strategy/NN
,/,
and/CC
make/VBP
it/PRP
possible/JJ
to/TO
perform/VB
a/DT
drug-related/JJ
knowledge/NN
discovery/RB
,/,
by/IN
incorporating/VBG
various/JJ
kinds/NNS
of/IN
heterogeneous/JJ
data/NNS
./.
====================
Trends/NNS
in/IN
BioNLP/NN
and/CC
drug-related/JJ
knowledge/NN
discovery/NN
====================
The/DT
goal/NN
of/IN
drug-related/JJ
discovery/NN
is/VBZ
to/TO
find/VB
novel/JJ
knowledge/NN
for/IN
extracting/VBG
drugs/NNS
,/,
and/CC
use/NN
the/DT
newly/RB
identified/VBN
drugs/NNS
for/IN
disease/NN
therapy/NN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
focused/VBD
on/IN
BioNLP/NN
and/CC
tensor/NN
or/CC
matrix/NN
decomposition/NN
methods/NNS
to/TO
predict/VB
novel/JJ
alternative/JJ
therapeutic/JJ
symptoms/NNS
./.
====================
Recent/JJ
progress/NN
in/IN
drug-related/JJ
knowledge/NN
discovery/NN
led/VBD
to/TO
a/DT
couple/JJ
of/IN
research/NN
trends/NNS
:/:
====================
(/(
1/CD
)/)
Well-annotated/JJ
corpora/NN
are/VBP
a/DT
core/NN
gold/NN
standard/JJ
dataset/NN
./.
====================
Annotation/NN
corpora/NN
are/VBP
crucial/JJ
to/TO
BioNLP/NN
,/,
and/CC
could/MD
help/VB
to/TO
retrieve/VB
and/CC
extract/NN
information/NN
from/IN
biomedical/JJ
text/RB
,/,
and/CC
also/RB
provide/VBP
standard/JJ
data/NNS
for/IN
repeatable/JJ
training/VBG
and/CC
evaluation/NN
of/IN
BioNLP/NN
./.
====================
(/(
2/CD
)/)
NER/NN
tasks/NNS
are/VBP
replaced/VBN
by/IN
more/RBR
complicated/VBN
knowledge/NN
curation/NN
tasks/NNS
,/,
in/IN
the/DT
BioNLP/NN
community/NN
./.
====================
Information/NN
from/IN
text/NN
can/MD
be/VB
extracted/VBN
by/IN
BioNLP/NN
,/,
which/WDT
could/MD
be/VB
the/DT
original/JJ
data/NNS
to/TO
find/VB
novel/JJ
knowledge/NN
through/IN
prediction/NN
models/NNS
./.
====================
With/IN
the/DT
recent/JJ
development/NN
of/IN
PubTator/NN
,/,
NER/NN
,/,
and/CC
term/NN
normalization/NN
,/,
are/VBP
properly/RB
solved/VBN
,/,
while/IN
aiming/VBG
to/TO
curate/VB
all/DT
of/IN
PubMed/JJ
./.
====================
(/(
3/CD
)/)
The/DT
application/NN
of/IN
BioNLP/NN
in/IN
drug-related/JJ
knowledge/NN
discovery/NN
requires/VBZ
deepened/VBN
integration/NN
of/IN
multi-omics/NNS
data/NNS
./.
====================
Cross-disciplinary/NN
collaboration/NN
among/IN
BioNLP/NN
,/,
MedNLP/NN
,/,
and/CC
bioinformatics/NNS
communities/NNS
is/VBZ
a/DT
promising/JJ
approach/NN
./.
====================
(/(
4/CD
)/)
Knowledge/NN
inference/NN
,/,
based/VBN
on/IN
tensor/NN
or/CC
matrix/NN
decomposition/NN
,/,
is/VBZ
regarded/VBN
as/IN
a/DT
reliable/JJ
prediction/NN
model/NN
./.
====================
The/DT
integration/NN
of/IN
algorithms/NNS
and/CC
theorems/NNS
,/,
developed/VBD
in/IN
knowledge/NN
graphs/NNS
,/,
is/VBZ
a/DT
promising/JJ
approach/NN
to/TO
resolve/VB
various/JJ
drug-related/JJ
knowledge/NN
discoveries/VBZ
./.
====================
BioNLP/NN
Open/JJ
Shared/JJ
Task/NN
:/:
AGAC/NN
track/VBP
====================
To/TO
encourage/VB
cross-disciplinary/JJ
collaboration/NN
from/IN
various/JJ
drug-related/JJ
knowledge/NN
discoveries/VBZ
,/,
shared/VBN
tasks/NNS
have/VBP
long/JJ
been/VBN
a/DT
stage/NN
to/TO
gather/RBR
researchers/NNS
with/IN
different/JJ
backgrounds/NNS
,/,
e.g./FW
,/,
the/DT
series/NN
of/IN
BioNLP/NN
Shared/JJ
Task/NN
(/(
BioNLP-ST/NN
)/)
workshops/VBZ
[/(
67-71/CD
]/)
./.
====================
Aiming/VBG
to/TO
gather/RBR
text/RB
mining/JJ
approaches/NNS
among/IN
the/DT
BioNLP/NN
community/NN
to/TO
propel/VB
drug-oriented/JJ
knowledge/NN
discovery/NN
,/,
BioNLP/NN
Open/JJ
Shared/JJ
Task/NN
workshop/NN
(/(
https/NNS
:/:
//2019.bionlp-ost.org/tasks/NNS
)/)
proposed/VBN
five/CD
sub-tasks/NNS
(/(
tracks/NNS
)/)
./.
====================
Among/IN
the/DT
five/CD
tasks/NNS
,/,
we/PRP
propose/VBP
a/DT
AGAC/NN
track/VBP
(/(
https/NNS
:/:
//sites.google.com/view/bionlp-ost19-agac-track/NN
)/)
,/,
for/IN
the/DT
goal/NN
of/IN
drug/NN
repurposing/VBG
./.
====================
AGAC/NN
track/VBP
provides/VBZ
an/DT
AGAC/NN
and/CC
aims/VBZ
to/TO
extract/NN
mutation-disease/NN
knowledge/NN
from/IN
PubMed/JJ
./.
====================
The/DT
mutation-disease/NN
knowledge/NN
in/IN
this/DT
track/NN
links/NNS
gene-mutation-function/NN
change/NN
to/TO
disease/NN
,/,
which/WDT
not/RB
only/RB
contains/VBZ
the/DT
relationship/NN
between/IN
mutation/NN
and/CC
disease/NN
,/,
but/CC
also/RB
indicates/VBZ
the/DT
functional/JJ
change/NN
of/IN
the/DT
mutation/NN
,/,
i.e./FW
,/,
GOF/NN
or/CC
LOF/NN
./.
====================
One/CD
application/NN
of/IN
this/DT
track/NN
is/VBZ
to/TO
elevate/VB
the/DT
efficiency/NN
of/IN
drug/NN
discovery/NN
,/,
since/IN
matching/VBG
drugs/NNS
with/IN
their/PRP$
target/NN
mutated/VBN
genes/NNS
must/MD
consider/VB
the/DT
corresponding/JJ
of/IN
the/DT
function/NN
change/NN
of/IN
mutated/VBN
gene/NN
and/CC
the/DT
pharmacological/JJ
activities/NNS
of/IN
drugs/NNS
./.
====================
AGAC/NN
track/VBP
contains/VBZ
three/CD
different/JJ
tasks/NNS
./.
====================
(/(
1/LS
)/)
Trigger/NNP
words/NNS
NER/NN
:/:
This/DT
task/NN
requires/VBZ
participants/NNS
to/TO
recognize/VB
trigger/VBP
words/NNS
from/IN
PubMed/JJ
abstracts/NNS
,/,
and/CC
annotate/JJ
them/PRP
with/IN
their/PRP$
corresponding/JJ
AGAC/NN
labels/NNS
or/CC
entities/VBZ
(/(
Var/JJ
,/,
MPA/NN
,/,
Interaction/NN
,/,
Pathway/NN
,/,
CPA/NN
,/,
Reg/NNP
,/,
PosReg/JJ
,/,
NegReg/JJ
,/,
Disease/NN
,/,
Gene/NN
,/,
Protein/NN
,/,
and/CC
Enzyme/NN
)/)
./.
====================
(/(
2/CD
)/)
Themetic/JJ
roles/NNS
identiftcation/NN
:/:
Identification/NN
of/IN
AGAC/NN
themetic/JJ
roles/NNS
(/(
e.g./FW
,/,
Theme/DT
Of/IN
,/,
Cause/NN
Of/IN
)/)
,/,
between/IN
trigger/VBP
words/NNS
./.
====================
(/(
3/CD
)/)
Gene-function/NN
mutation-disease/NN
link/NN
discovery/NN
:/:
Extract/JJ
the/DT
gene-/NN
(/(
mutation/NN
)/)
-function/NN
change-biology/NN
function/NN
or/CC
disease/NN
link/NN
./.
====================
For/IN
example/NN
,/,
“/NNP
Mutations/NNS
in/IN
SHP-2/NN
phosphatase/NN
that/WDT
cause/VBP
hyperactivation/NN
of/IN
its/PRP$
catalytic/JJ
activity/NN
have/VBP
been/VBN
identified/VBN
in/IN
human/JJ
leukemias/NNS
,/,
particularly/RB
juvenile/IN
myelomonocytic/JJ
leukemia./FW
”/CD
From/IN
this/DT
sentence/NN
,/,
the/DT
participants/NNS
need/RB
to/TO
extract/NN
(/(
SHP-2–GOF–juvenile/JJ
myelomonocytic/JJ
leukemia/NN
)/)
./.
====================
The/DT
baseline/NN
methods/NNS
for/IN
task/NN
1/CD
or/CC
2/CD
was/VBD
performed/VBN
in/IN
Zhou/NNP
et/FW
al./FW
’/CD
s/NNS
work/NN
[/(
65/CD
]/)
,/,
while/IN
the/DT
“/NN
agonist/NN
vs./CC
LOF/NN
”/CD
and/CC
“/FW
antagonist/NN
vs./CC
GOF/NN
”/CD
hypothesis/NN
for/IN
the/DT
support/NN
of/IN
drug/NN
repurposing/VBG
was/VBD
proposed/VBN
in/IN
Wang/NNP
and/CC
Zhang/NNP
’/CD
s/NNS
work/NN
[/(
18/CD
]/)
./.
====================
The/DT
development/NN
of/IN
the/DT
AGAC/NN
corpus/NN
[/(
38/CD
]/)
laid/NN
the/DT
basis/NN
for/IN
the/DT
data/NNS
availability/NN
,/,
while/IN
PubAnnotation/NN
[/(
72/CD
]/)
served/VBD
as/IN
the/DT
evaluation/NN
platform/NN
./.
====================
Structure/NN
of/IN
a/DT
matrix/NN
and/CC
a/DT
three/CD
way/NN
tensor/NN
./.
====================
